Performance of GSK GlaxoSmithKline PLC ADR | 27.7% in 12m
Compare GSK with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare GlaxoSmithKline PLC ADR with its related Sector/Index XLV
Performance Duell GSK vs XLV
TimeFrame | GSK | XLV |
---|---|---|
1 Day | 0.47% | 1.33% |
1 Week | 2.53% | 1.55% |
1 Month | 1.44% | 1.02% |
3 Months | 17.0% | 9.09% |
6 Months | 18.4% | 15.34% |
12 Months | 27.7% | 17.46% |
YTD | 15.7% | 6.82% |
Rel. Perf. 1m | 0.11 | |
Rel. Perf. 3m | 0.79 | |
Rel. Perf. 6m | 0.27 | |
Rel. Perf. 12m | 0.82 |
Is GlaxoSmithKline PLC ADR a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, GlaxoSmithKline PLC ADR (NYSE:GSK) is currently (March 2024)
ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 3.72 and therefor a somewhat positive outlook according to fundamental data.
Based on ValueRays Technical Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GSK as of March 2024 is 40.66. This means that GSK is currently overvalued and has a potential downside of -5.42%.
Based on ValueRays Technical Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GSK as of March 2024 is 40.66. This means that GSK is currently overvalued and has a potential downside of -5.42%.
Is GSK a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 4
- Sell: 1
- Strong Sell: 0
Values above 0%: GSK is performing better - Values below 0%: GSK is underperforming
Compare GSK with Broad Market Indices
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 2.01% | -2.08% | -5.31% | -6.21% |
US NASDAQ 100 | QQQ | 2.29% | -0.35% | -7.40% | -17.38% |
US Dow Jones Industrial 30 | DIA | 1.88% | -0.83% | -1.27% | 2.69% |
German DAX 40 | DBXD | -0.08% | -3.85% | -3.06% | 6.15% |
UK FTSE 100 | ISFU | 0.69% | -1.83% | 7.98% | 14.41% |
Shanghai Shenzhen CSI 300 | CSI 300 | 5.57% | 1.69% | 23.35% | 43.50% |
Hongkong Hang Seng | HSI | 4.96% | 6.76% | 24.31% | 47.45% |
Japan Nikkei 225 | EXX7 | 1.34% | -1.39% | -2.48% | -0.02% |
India NIFTY 50 | INDA | 1.20% | 2.49% | 3.79% | -4.79% |
Brasil Bovespa | EWZ | 3.47% | 6.05% | 6.39% | -4.61% |
GSK GlaxoSmithKline PLC ADR vs. Sectors
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 2.32% | -2.11% | -7.68% | -18.90% |
Consumer Discretionary | XLY | 1.88% | 0.12% | 1.43% | -3.38% |
Consumer Staples | XLP | 2.15% | -1.69% | 5.86% | 20.66% |
Energy | XLE | 1.06% | -8.18% | 15.21% | 6.18% |
Financial | XLF | 1.74% | -3.13% | -8.75% | -8.05% |
Health Care | XLV | 0.98% | 0.42% | 3.03% | 10.19% |
Industrial | XLI | 1.30% | -3.64% | -6.79% | -3.39% |
Materials | XLB | 1.35% | -5.88% | -1.91% | 5.47% |
Real Estate | XLRE | 1.63% | -1.79% | -0.58% | 12.70% |
Technology | XLK | 2.99% | -0.21% | -10.79% | -17.64% |
Utilities | XLU | 0.45% | -4.78% | 8.01% | 25.11% |
Aerospace & Defense | XAR | 1.65% | -1.85% | -7.81% | 3.92% |
Biotech | XBI | 2.79% | 9.20% | -9.92% | 0.99% |
Homebuilder | XHB | 0.49% | -6.83% | -27.48% | -43.21% |
Retail | XRT | 1.20% | -1.01% | -14.56% | -3.94% |
Does GlaxoSmithKline PLC ADR outperform its market, is GSK a Sector Leader?
Yes, over the last 12 months GlaxoSmithKline PLC ADR (GSK) made 27.65%, while its related Sector, the Health Care Sector SPDR Fund (XLV) made 17.46%.
Over the last 3 months GSK made 17.01%, while XLV made 9.09%.
Yes, over the last 12 months GlaxoSmithKline PLC ADR (GSK) made 27.65%, while its related Sector, the Health Care Sector SPDR Fund (XLV) made 17.46%.
Over the last 3 months GSK made 17.01%, while XLV made 9.09%.
Period | GSK | XLV | S&P 500 |
---|---|---|---|
1 Month | 1.44% | 1.02% | 3.52% |
3 Months | 17.01% | 9.09% | 10.13% |
12 Months | 27.65% | 17.46% | 33.86% |